Similar articles

• CHARISMA: the antiplatelet saga continues.

  Norris JW, Barnett HJ. Norris JW, et al. Stroke. 2006 Sep;37(9):2428-9. doi: 10.1161/01.STR.0000236037.87109.fc. Epub 2006 Jul 20. Stroke. 2006. PMID: 16857946 No abstract available.
• Antiplatelet agents for stroke prevention.

  Paciaroni M, Gallai V. Paciaroni M, et al. Cerebrovasc Dis. 2000;10 Suppl 4:36-9. doi: 10.1159/000047592. Cerebrovasc Dis. 2000. PMID: 11070399 Review. No abstract available.
• Update on the use of antiplatelet agents in secondary stroke prevention.

  Jamieson DG. Jamieson DG. J Natl Med Assoc. 2007 Mar;99(3):306. J Natl Med Assoc. 2007. PMID: 17393957 Free PMC article. No abstract available.
• The charisma of subgroups and the subgroups of CHARISMA.

  Pfeffer MA, Jarcho JA. Pfeffer MA, et al. N Engl J Med. 2006 Apr 20;354(16):1744-6. doi: 10.1056/NEJMe068061. Epub 2006 Mar 12. N Engl J Med. 2006. PMID: 16531617 No abstract available.
• Antiplatelet therapy to prevent recurrent stroke: Three good options.

  Mansoor AH, Mujtaba MT, Silver B. Mansoor AH, et al. Cleve Clin J Med. 2013 Dec;80(12):787-95. doi: 10.3949/ccjm.80a.12149. Cleve Clin J Med. 2013. PMID: 24307163 Review.